Manmeet S. Ahluwalia, MD, MBA, FASCO, is the deputy pirector, chief scientific officer, chief of medical oncology, and Fernandez Family Foundation Endowed Chair in Cancer Research at Miami Cancer Institute, which is part of Baptist Health South Florida.

Dr Ahluwalia on the Evolution of Precision Medicine in Oncology

“I could not be more thrilled about the remarkable pace of transformative changes that we are collectively making in oncology. We are living in the best era of mankind, where we have artificial intelligence, which can help us with finding better information with the genomic testing that we offer to all of our patients who come to see us at Miami Cancer Institute.”

Manmeet Singh Ahluwalia, MD, MBA, FASCO, chief scientific officer, chief, medical oncology, deputy director, Fernandez Family Endowed Chair in Cancer Research, Baptist Health Miami Cancer Institute, discusses advances in oncology research and patient care across cancer types that were highlighted at the Third Annual Miami Cancer Institute Precision Oncology Symposium.

The field of oncology is undergoing a rapid and transformative evolution, driven by advancements in artificial intelligence, genomic testing, and precision medicine, Ahluwalia begins. At Miami Cancer Institute, a multidisciplinary cancer management approach ensures patients receive individualized treatment strategies based on the latest scientific insights, he says. Meetings such as the Miami Cancer Institute Precision Oncology Symposium serve as crucial platforms for disseminating groundbreaking information, allowing for the continuous refinement of treatment protocols, he explains.

Significant progress has been made across multiple oncology specialties, with stage IV lung cancer serving as a prime example, according to Ahluwalia. Approximately 2 decades ago, the median overall survival (OS) for these patients was approximately 12 months, and the 5-year OS rate was approximately 5%, he notes. Now, however, the median OS in this population has extended to approximately 2.5 years, with 5-year survival rates reaching approximately 20%, he reports.

Miami Cancer Institute places a strong emphasis on remaining at the forefront of scientific and clinical advancements, Ahluwalia states. Strategic partnerships with institutions like Florida International University facilitate translational research, bridging the gap between bench discoveries and bedside applications, he says. Additionally, collaborations with leading cancer centers worldwide foster valuable exchanges of expertise and novel therapeutic strategies, he concludes.

Videos

Manmeet Singh Ahluwalia, MD, MBA, FASCO, discusses oncology advances that were highlighted at the Miami Cancer Institute Precision Oncology Symposium.

Ongoing advances in immunotherapies and increasingly precise targeted drug therapies have brought an optimistic and encouraging outlook for cancer care in 2024. Yet, for the first time in history, the US is predicted to hit a new sobering cancer milestone: More than 2 million people are estimated to be diagnosed with cancer in 2024 (nearly 5500 new cases per day), according to the latest statistics from the American Cancer Society’s annual outlook report.

The number gives rise to concern because, despite innovations in care, significant challenges remain, particularly in overcoming long-established health disparities that prevent equal access to diagnostic care, standard-of-care therapies, and novel treatments. For example, more than 90% of drug trial participants identify as White. It’s a statistic that is of grave concern to clinicians everywhere, but it is especially concerning to those in South Florida, where most of the population has origins in Latin America and the Caribbean.

The problem has garnered widespread attention, and the FDA’s latest guidance documents now recommend that study designers and investigators discuss plans for increasing diversity early in the process.

 Without adequate representation of underrepresented populations in a clinical trial, the postapproval requirements of the drug may be affected, the FDA reports.

Baptist Health Miami Cancer Institute launched the Center for Equity in Cancer Care & Research to address this issue. Its mission is to identify and decrease disparities in cancer care and to improve participation of underrepresented populations in clinical trials. With approximately 200 trials open at the institute, part of the center’s goal is to ensure that the latest advances are reaching all patients with cancer.

However, we know cancer incidence is not the same across all ethnicities; for example:

The incidence of major cancers (ie, lung, colorectal, kidney) among Black men is higher than for White men.

Black women have a higher incidence of cancers with low survival, such as stomach and pancreas cancer.

Black women are nearly twice as likely to die of uterine cancer than White women.

The incidence of prostate cancer is 70% higher in Black men than in White men, and mortality rates in Black individuals are twice as high when compared with White individuals.

In general, Hispanic individuals are less likely to be diagnosed with cancer than White individuals but have a higher incidence of specific types of cancer. For example, Hispanic men and women have nearly double the incidence and mortality rates of liver and stomach cancers compared with White individuals.

In terms of clinical trial participation, Miami Cancer Institute is working closely with patient navigators, community health workers, and local faith-based organizations to educate people and to reduce some of the cultural mistrust that exists among underrepresented populations. In addition to boosting diverse participation in clinical trials by 50% over the next 2 to 3 years and increasing numbers in cancer screenings, Miami Cancer Institute’s Center for Equity in Cancer Care & Research is also taking a close look at the many social determinants of health that can negatively impact outcomes. One area we are continuing to develop is our Spanish-language materials, because approximately 20% of the institute’s patients indicate that they do not read English well enough to understand consent forms.

The institute is also working on increasing screening numbers of cancer detection in alignment with President Joseph R. Biden’s Cancer Moonshot program that aims to decrease the age-adjusted cancer death rate by 50% in the next 25 years.

 The American Lung Association’s 2023 report, “State of Lung Cancer,” stated that Florida’s lung cancer screening rate of 2.4% was far below the national average of 4.5%.

To build awareness and encourage those at highest risk to undergo lung cancer screenings, Baptist Health and the American Lung Association joined forces in 2021 as part of the “Saved by the Scan” campaign.

 The partnership was the first between a large health care organization and the American Lung Association, and it produced encouraging results. The campaign resulted in a 55% increase in lung cancer screenings, using low-dose CT scans. Additionally, Baptist Health has partnered with the LUNGevity Foundation, which is the nation’s leading lung cancer–focused nonprofit organization, to set up a screening program targeting the Hispanic/Latino community.

As we work together to focus our efforts on providing equal access to high-quality care for all, the cancer community pushes forward on cutting-edge trials and advances that are leading to longer survival, improved quality of life, and cures. There’s every reason to have an optimistic outlook for cancer care in 2024.

Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. 

. 2024;74(1):12-49. doi:10.3322/caac.21820

Diversity plans to improve enrollment of participants from underrepresented racial and ethnic populations in clinical trials; draft guidance for industry; availability. FDA. April 13, 2022. Accessed March 5, 2024. 

https://www.fda.gov/regulatory-information/search-fda-guidance-documents/diversity-plans-improve-enrollment-participants-underrepresented-racial-and-ethnic-populations

Fernandez J. Cancer care outlook 2024: more treatment advances and more minority involvement in clinical trials. Baptist Health South Florida blog. February 5, 2024. Accessed March 5, 2024. 

https://baptisthealth.net/baptist-health-news/more-treatment-advances-and-more-minority-involvement-in-clinical-trials

NIH study outlines opportunities to achieve President Biden’s Cancer Moonshot goal of reducing cancer death rates in the United States. News release. National Institutes of Health. April 17, 2023. Accessed March 5, 2024. https://www.nih.gov/news-events/news-releases/nih-study-outlines-opportunities-achieve-president-biden-s-cancer-moonshot-goal-reducing-cancer-death-rates-united-states 

American Lung Association. State of Lung Cancer 2023 Report. American Lung Association. Accessed March 5, 2024. https://www.lung.org/getmedia/186786b6-18c3-46a9-a7e7-810f3ce4deda/SOLC-2023-Print-Report.pdf 

Articles

Although novel therapies have improved cancer care, cancer diagnoses have increased, with more than 2 million new cases estimated for 2024.

Manmeet S. Ahluwalia, MD, MBA, FASCO

Articles

Dr Ahluwalia on the Evolution of Precision Medicine in Oncology

2024 Outlook on Cancer Care: Striving to Overcome the Challenges